Senseonics resumed with a Hold at Stifel

Stifel resumed coverage of Senseonics (SENS) with a Hold rating and $9 price target The firm views its physician diligence “favorably” and identifies increasing Eversense 365-day share gains across several segments of the T2 market and calls out Gemini as being “in the impressive number three slot among CGM innovations.” However, Senseonics soon taking commercial operations back from Ascensia will likely require additional capital, notes the analyst, who also feels the Freedom sensor due in the back half of 2027 is “the form factor that will matter most for physicians and patients.”